Cambridge Investment Research Advisors, Inc. Lexicon Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 21,500 shares of LXRX stock, worth $22,575. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,500
Previous 22,075
2.6%
Holding current value
$22,575
Previous $10,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding LXRX
# of Institutions
135Shares Held
199MCall Options Held
310KPut Options Held
77.3K-
Artal Group S.A. Luxembourg, N4136MShares$143 Million100.0% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$10.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.56MShares$10 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY8.21MShares$8.62 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA3.69MShares$3.87 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $198M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...